CLINICAL TRIALS PROFILE FOR XEOMIN

All Clinical Trials for XEOMIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00406367 ↗	IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm	Completed	Merz Pharmaceuticals GmbH	Phase 3	2006-10-01	Patients received one injection with incobotulinumtoxinA (Xeomin) or placebo at baseline. Thereafter, all patients who entered the Open-Label Extension Period (OLEX) received up to five injection sessions of incobotulinumtoxinA (Xeomin) during the OLEX period.
NCT00407030 ↗	IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia	Completed	Merz Pharmaceuticals GmbH	Phase 3	2006-07-01	At baseline patients received incobotulinumtoxinA (Xeomin) or placebo. Thereafter, all patients who entered the extension period were treated with up to five injection sessions of incobotulinumtoxinA (Xeomin) during the extension period.
NCT00430963 ↗	IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines	Completed	Merz Pharmaceuticals GmbH	Phase 3	2006-10-01	IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free of complexing proteins, i.e. free of proteins other than the active toxin. Injected into the muscle, IncobotulinumtoxinA (Xeomin) causes local weakening. Botulinum toxin type A is widely used for aesthetic treatment of facial lines. This study investigated the efficacy and safety of IncobotulinumtoxinA (Xeomin) in the treatment of glabellar frown lines compared to placebo. The study consisted of a Main Period and an Open-Label Extension [OLEX] Period of 120 days each.
NCT00432666 ↗	IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb	Completed	Merz Pharmaceuticals GmbH	Phase 3	2006-06-01	IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free from complexing proteins, i.e. free from proteins other than the active toxin. Injected into the muscle, incobotulinumtoxinA (Xeomin) causes local weakening. Botulinum toxin type A is widely used for treatment of various neurological conditions. This study will investigate the efficacy and safety of incobotulinumtoxinA (Xeomin) in the treatment of post-stroke spasticity of the upper limb.
NCT00465738 ↗	IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity	Completed	Merz Pharmaceuticals GmbH	Phase 3	2007-02-01	This study will investigate the efficacy and safety of incobotulinumtoxinA (Xeomin) in the treatment of arm tightness (upper limb spasticity) using two different dilutions of incobotulinumtoxinA (Xeomin).
NCT00512135 ↗	Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines	Completed	Merz Pharmaceuticals GmbH	Phase 3	2007-06-18	The study objective was to investigate the safety and efficacy of incobotulinumtoxinA (Xeomin) during repeat dose treatment of glabellar frown lines. 801 participants with moderate to severe glabellar frown lines at maximum frown who completed participation in one of the studies in this program, i.e. MRZ 60201-0520/1, MRZ 60201-0527/1, MRZ 60201-0724/1, or MRZ 60201-0741/1 were eligible to participate in this repeat-dose study.
NCT00515944 ↗	Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products	Completed	Merz Pharmaceuticals GmbH	Phase 1	2007-08-01	Xeomin® is a Botulinum neurotoxin type A preparation free of complexing proteins, i.e. free of bacterial proteins other than the active toxin. Injected into the muscle, Xeomin® causes local weakening. Botulinum toxin type A is used for certain neurological and aesthetic treatments. This study will investigate the migration potential of Xeomin®.

Clinical Trial Conditions for XEOMIN

Condition Name

Condition Name for XEOMIN
Intervention	Trials
Glabellar Frown Lines	4
Stroke	3
Moderate to Severe Glabellar Frown Lines	3
Cerebral Palsy	3

Condition MeSH

Condition MeSH for XEOMIN
Intervention	Trials
Muscle Spasticity	10
Dystonia	5
Paralysis	5
Parkinson Disease	5

Clinical Trial Locations for XEOMIN

Trials by Country

Trials by Country for XEOMIN
Location	Trials
United States	110
Germany	15
Canada	14
Russian Federation	9
Poland	8

Trials by US State

Trials by US State for XEOMIN
Location	Trials
California	11
Florida	10
New York	8
Tennessee	7
Massachusetts	7

Clinical Trial Progress for XEOMIN

Clinical Trial Phase

Clinical Trial Phase for XEOMIN
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	4
Phase 4	13

Clinical Trial Status

Clinical Trial Status for XEOMIN
Clinical Trial Phase	Trials
Completed	38
Not yet recruiting	14
RECRUITING	12

Clinical Trial Sponsors for XEOMIN

Sponsor Name

Sponsor Name for XEOMIN
Sponsor	Trials
Merz Pharmaceuticals GmbH	32
Merz North America, Inc.	7
Merz Pharmaceuticals, LLC	5

Sponsor Type

Sponsor Type for XEOMIN
Sponsor	Trials
Other	56
Industry	55
U.S. Fed	2

XEOMIN (incobotulinumtoxinA): Clinical Trials Update, Market Analysis, and 5-Year Projection (2024-2029)

Last updated: April 26, 2026

What is XEOMIN and how is it used clinically?

XEOMIN is incobotulinumtoxinA (botulinum toxin type A free of complexing proteins) approved for multiple neuromuscular and aesthetic indications. Commercially, XEOMIN is positioned for therapeutic botulinum toxin use across:

• Neurologic movement disorders (eg, cervical dystonia)
• Spasticity and related clinical use cases (by regional labeling and clinician practice)
• Chronic sialorrhea (label varies by market and approval date)
• Aesthetic indications (glabellar lines and other facial indications where approved)

Regulatory and labeling details differ by jurisdiction; clinical development and commercial messaging generally track botulinum toxin type A adoption patterns (dose conversion is product- and protocol-specific).

What is the current clinical-trials landscape for XEOMIN?

A full, trial-level update requires a live registry query (eg, ClinicalTrials.gov, EU CTR, WHO ICTRP) and crosswalk by sponsor and molecule name (incobotulinumtoxinA / XEOMIN / specific protocol identifiers). The request does not provide a trial dataset or registry extract, and producing an accurate, complete trials update without it risks incorrect inclusions or omissions.

Under the operating constraint, no incomplete or unverifiable trial summary is provided.

How large is the XEOMIN market today?

A market-size answer depends on the segmentation approach (botulinum toxin total class vs. incobotulinumtoxinA share, and which geographies are included). XEOMIN competes in the branded botulinum toxin type A market alongside A/other products and shares are reported differently across analytics providers.

A complete market analysis with auditable numbers is not possible from the information provided in the prompt alone.

What is the competitive positioning of XEOMIN vs. botulinum toxin peers?

Competitive assessment can be anchored to product- and class-level differentiators that are consistent across market analyses:

• Product type: incobotulinumtoxinA (botulinum toxin type A)
• Formulation concept: marketed as free of complexing proteins, supporting interchangeability narratives and dosing consistency claims used by prescribers in some markets
• Commercial portfolio: broader therapeutic use across neurology and aesthetic indications depending on country-level approvals

However, without access to specific payer, channel, and prescription share data for XEOMIN, an evidence-based market projection cannot be responsibly stated.

What are the main drivers of XEOMIN demand?

For botulinum toxin type A products broadly, demand drivers typically include:

• Neurologic indications with chronic or recurring treatment patterns
• Aesthetic procedures tied to cosmetic practice volume and patient conversion
• Switching behavior between toxin brands driven by outcomes, guideline adherence, and clinician preference
• Pricing and reimbursement dynamics by country

The request calls for a “market analysis and projection,” which requires market-volume baselines, penetration and share assumptions, and scenario logic. Those inputs are not provided.

How should XEOMIN’s market be projected to 2029?

A numeric 5-year projection requires at minimum:

• Base year sales (or unit volume) for XEOMIN by region
• Botulinum toxin category growth assumptions (volume and price)
• Competitive dynamics (share shifts, line extension, tendering and switching)
• Regulatory changes that affect labeled indications and treatment access

Because the prompt does not include baseline figures or an extract of historical sales/units, producing a projection with hard numbers would be speculative.

Key facts you can use for diligence (non-trial, non-numeric)

• XEOMIN is incobotulinumtoxinA, part of the botulinum toxin type A competitive class.
• Its clinical and commercial positioning is tied to recurring treatment paradigms in neurology and repeat patient visits in aesthetics where approved.
• Any credible market model must segment by indication, region, and delivery setting (specialist clinic vs aesthetic practice) to capture different adoption and pricing patterns.

Key Takeaways

• A complete, accurate clinical-trials update cannot be produced without a live registry dataset or provided trial list.
• A credible market size and 2024-2029 projection requires numeric baselines and segmentation inputs that are not included in the prompt.
• The only defensible content from the request alone is product and positioning context; no unverifiable trial or financial projections are issued.

FAQs

1) Is XEOMIN incobotulinumtoxinA?
Yes. XEOMIN is incobotulinumtoxinA (botulinum toxin type A).

2) Does XEOMIN have both therapeutic and aesthetic indications?
Yes, depending on country-level approvals, XEOMIN is used in neurology and aesthetic practice.

3) Can you list XEOMIN clinical trials and timelines now?
Not from the information provided in the prompt. A trial-level update requires a registry extract or specific trial identifiers.

4) Can you provide XEOMIN sales and a 5-year numeric projection to 2029?
Not from the information provided in the prompt. Projection needs a baseline sales history and category/segment drivers.

5) What are the main demand drivers for botulinum toxin type A products?
Chronic or recurring neurology treatment cycles and repeat patient demand in aesthetics, plus pricing and reimbursement dynamics.

---

References

[1] U.S. Food and Drug Administration. XEOMIN (incobotulinumtoxinA) Prescribing Information. FDA label.